Distributor inventory | Tablet
Linagliptin 5 mg + Metformin 500 mg (as Metformin Hydrochloride)
Treatment of type 2 diabetes mellitus to improve glycaemic control (along with diet and exercise), especially when metformin alone or linagliptin alone is insufficient
Linagliptin is a DPP-4 inhibitor that increases incretin hormones (GLP-1, GIP), leading to increased insulin release and reduced glucagon in a glucose-dependent manner. Metformin decreases hepatic glucose production and improves peripheral insulin sensitivity, thereby lowering blood glucose.
Oral tablet; take exactly as prescribed. Usually taken with meals to reduce stomach upset; swallow whole with water. Do not crush/chew; follow dosing schedule advised by doctor and monitor blood glucose regularly.
Common side effects of LINABITE M 5/500 TAB may include:
Not for type 1 diabetes or diabetic ketoacidosis. Metformin can rarely cause lactic acidosis—risk increases with severe kidney disease, dehydration, sepsis, alcohol excess, liver disease, or hypoxia; assess renal function before and during therapy. Temporarily stop metformin around iodinated contrast procedures and major surgery as advised by doctor. Use caution in elderly and in patients with renal/hepatic impairment; seek care for severe abdominal pain (possible pancreatitis), persistent vomiting, rapid breathing, or unusual muscle pain/weakness.
